CAS: 432529-82-3

BCI-121

BCI-121

BCI-121 is an investigational drug that inhibits the enzyme lysine methyltransferase (KMT), which is involved in the methylation of histones and other cellular proteins. BCI-121 has been shown to inhibit tumor growth and induce tumor cell death by inhibiting mitochondrial functions. The mechanism of action for BCI-121 involves epigenetic regulation of gene expression, meaning that it controls the activity of genes without altering their DNA sequence. In cancer cells, BCI-121 inhibits the synthesis of DNA, RNA, and protein, leading to apoptosis. This drug also shows potential for treating inflammatory diseases such as rheumatoid arthritis by inhibiting KMT activity in immune cells.

BCI-121 is a substrate-competitive SMYD3 inhibitor that inhibits the proliferation of the cancer cell.